References
- Willemze R, Jaffe ES, Burg G et al. WHO–EORTC classification for cutaneous lymphomas. Blood105, 3768–3785 (2005).
- Kaye FJ, Bunn PA Jr, Steinberg SM et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N. Engl. J. Med.321, 1784–1790 (1989).
- Poszepczynska-Guigne E, Bagot M, Wechsler J, Revuz J, Farcet JP, Delfau-Larue MH. Minimal residual disease in mycosis fungoides follow-up can be assessed by polymerase chain reaction. Br. J. Dermatol.148, 265–271 (2003).
- Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol.25, 3109–3115 (2007).
- Marchi E, Alinari L, Tani M et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: Phase II study of 32 patients. Cancer104, 2437–2441 (2005).
- Wollina U, Dummer R, Brockmeyer NH et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer98, 993–1001 (2003).
- Bernengo MG, Quaglino P, Comessatti A et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica92, 784–794 (2007).
- Kim YH, Duvic M, Obitz E et al. Clinical efficacy of zanolimumab (HuMax-CD4): two Phase 2 studies in refractory cutaneous T-cell lymphoma. Blood109, 4655–4662 (2007).
- Bagot M, Moretta A, Sivori S et al. CD4+ cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood97, 1388–1391 (2001).
- Poszepczynska-Guigné E, Schiavon V, D’Incan M et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J. Invest. Dermatol.122, 820–823 (2004).